An independent two-stage DCF analysis by a frontier AI model.
Merck faces a significant patent cliff for its blockbuster drug Keytruda in 2028. While their pipeline (Prometheus acquisition, Harpoon Therapeutics, ADC collaborations) is robust, replacing $25B+ in annual revenue is a massive hurdle. A 4% growth rate reflects moderate near-term growth offset by the impending cliff, requiring successful pipeline execution just to maintain this trajectory.
A Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow (DCF) Analysis
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $101.20 | $82.80 | $70.06 | $60.72 | $53.58 |
| 1.5% | $113.85 | $91.08 | $75.90 | $65.06 | $56.92 |
| 2.0% | $130.11 | $101.20 | $82.80 | $70.06 | $60.72 |
| 2.5% | $151.80 | $113.85 | $91.08 | $75.90 | $65.06 |
| 3.0% | $182.16 | $130.11 | $101.20 | $82.80 | $70.06 |
■ Undervalued vs current price ■ Overvalued vs current price
This is the single biggest risk. Keytruda generates a massive portion of Merck's revenue. If the pipeline fails to adequately offset the revenue loss from biosimilar competition starting in 2028, these FCF projections will be overly optimistic.
Merck has aggressively pursued acquisitions (like Prometheus) and partnerships (like Daiichi Sankyo) to bolster its pipeline. Clinical trial failures or regulatory setbacks for these assets would severely impact future growth.
Changes in healthcare policy, particularly the Inflation Reduction Act (IRA) in the US, could mandate price negotiations for successful drugs, squeezing margins and reducing future cash flows.
Merck faces a massive patent cliff for its flagship oncology drug, Keytruda, in 2028. Keytruda currently accounts for roughly 40% of their total revenue. A 4% growth rate factors in the immense challenge of replacing this revenue through their pipeline and recent acquisitions.
The patent expiration is the primary driver of risk in this model. It suppresses the terminal growth rate (2.0%) and elevates the required discount rate (7.5%) to account for the execution risk of successfully commercializing the pipeline to offset the impending revenue gap.
According to this independent analysis by Gemini 3.1, MRK's estimated intrinsic value is $82.80 per share. Compared to the current price of $114.51, it appears overvalued with a margin of safety of 27.7%.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.